Expertise in

conditions

Albert C. Ludolph

Albert Einstein Allee 11,

Ulm, BW, DE

Expertise in

conditions

Albert Einstein Allee 11,

Ulm, BW, DE

Overview

Albert Ludolph practices practicing medicine in Ulm, Germany.

Mr. Ludolph is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Gastrostomy, and Thrombectomy.

He is actively involved in clinical research, co-authoring 635 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Albert Einstein Allee 11, Ulm, BW 89081, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)

Enrollment Status: Completed

Publish Date: August 19, 2025

Intervention Type: Drug

Study Drug: AP-101

Study Phase: Phase 2

Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol

Enrollment Status: Completed

Publish Date: June 29, 2025

Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial

Enrollment Status: Terminated

Publish Date: August 24, 2023

Intervention Type: Drug

Study Drug: Arimoclomol

Study Phase: Phase 3

A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis

Enrollment Status: Completed

Publish Date: August 24, 2023

Intervention Type: Drug

Study Phase: Phase 3

Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)

Enrollment Status: Unknown

Publish Date: July 10, 2023

Intervention Type: Drug

Study Drug: Tauroursodexycholic Acid

Study Phase: Phase 3

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study

Enrollment Status: Completed

Publish Date: April 12, 2021

Intervention Type: Other

Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome

Enrollment Status: Completed

Publish Date: September 11, 2019

Intervention Type: Procedure

Study Phase: Not Applicable

View 6 Less Clinical Trials

632 Total Publications

Author Correction: FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis.

Journal: Nature neuroscience

Published: July 16, 2026

View All 632 Publications

Frequently Asked Questions about Albert C. Ludolph

Is Albert C. Ludolph a top-rated expert for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)?

MediFind is an objective health platform that identifies experts based on real-world data. Albert C. Ludolph is classified as an Elite expert for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Albert C. Ludolph participate in research or clinical trials?

Yes. Albert C. Ludolph has published 632 articles and abstracts on conditions like Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). You can view a list of Albert C. Ludolph's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ludolph's expertise for a condition

ConditionClose